Peter Gregory Goekjian

Title: Peter Gregory Goekjian: Innovator in Cellular Necroptosis Inhibition

Introduction

Peter Gregory Goekjian is a notable inventor based in Lyons, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit cellular necroptosis. With a total of 6 patents to his name, Goekjian's work is paving the way for advancements in medical treatments.

Latest Patents

Goekjian's latest patents focus on substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis. The first patent describes new N- and N-substituted sibiriline derivatives, which are intended for use as drugs, specifically as inhibitors of cellular necroptosis. This invention also includes a pharmaceutical composition comprising such compounds and outlines processes for their preparation. Additionally, it encompasses the use of these compounds for organ preservation. The second patent further explores sibiriline derivatives for preventing and/or treating disorders associated with cellular necroptosis, emphasizing their potential in pharmaceutical applications.

Career Highlights

Throughout his career, Goekjian has worked with esteemed institutions such as Université Claude Bernard Lyon 1 and the Centre National de la Recherche Scientifique. His research has significantly impacted the understanding and treatment of cellular necroptosis, showcasing his dedication to advancing medical science.

Collaborations

Goekjian has collaborated with notable colleagues, including Luca Mologni and Leonardo Scapozza. These partnerships have contributed to the success of his research and the development of innovative solutions in the pharmaceutical field.

Conclusion

Peter Gregory Goekjian's contributions to the field of cellular necroptosis inhibition highlight his role as a leading inventor in pharmaceuticals. His innovative patents and collaborations reflect his commitment to advancing medical science and improving treatment options.